XTalks
AUGUST 25, 2023
After seeking approval in May to settle litigations over pricing of its insulin product Humalog, Eli Lilly is facing resistance from nine US states who are asking a New Jersey federal court to delay approval of the proposed $13.5 US insulin makers have come under fire as the US is the country with the most expensive insulin in the world.
Delveinsight
JULY 21, 2021
However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease. It is also known as insulin-dependent diabetes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
FEBRUARY 9, 2022
Findings from an analysis conducted by Constella Intelligence , a digital risk protection company, show widespread cybersecurity vulnerabilities that are costing pharma companies significantly. The report includes information on breaches, exposures and leaks in the pharma sphere.
Pharmaceutical Technology
JANUARY 31, 2023
Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices. That leaves three years for pharma companies to prepare.
XTalks
FEBRUARY 14, 2024
US drug pricing has been under fire for many years and things took a significant turn last year when the three major insulin makers (Eli Lilly, Sanofi and Novo Nordisk) decided to slash the price of their insulin products and agreed to cap out-of-pocket costs at $35 per month for patients with insurance coverage.
XTalks
FEBRUARY 21, 2024
Similar to tirzepatide, dulaglutide stimulates insulin secretion, inhibits glucagon release and promotes satiety. These candidate drugs are a small sample from a diverse array of GLP-1 receptor agonists that are being tested by pharma companies in varying formulations, dosing regimens and clinical profiles.
XTalks
JANUARY 5, 2024
Related: Zepbound, Obesity Version of Eli Lilly’s Mounjaro, Finally Gets FDA Nod So far, LillyDirect provides support for 14 Lilly medicines, with 12 being different formulations and types of insulin. In addition to these and Zepbound, Lilly’s medication for migraine management, Emgality (galcanezumab), is also available through the website.
Expert insights. Personalized for you.
52 
Let's personalize your content